ABOUT Cystistat®

CYSTISTAT® efficacy

BPS/IC 16

Cystistat® is effective from the primary therapy. 10

  • 85 % of patients observed symptom improvement after initial treatment. 1
  • 84 % of patients reported quality of life improvement. 9

cystistat®: response rate in BPS/IC in several studies

cystistat: response rate in BPS/IC in several studies

Cystistat®: mean reduction of the symptoms after 3 months therapy

Cystistat: mean reduction of the symptoms after 3 months therapy

Evolution of pain or bladder symptoms: Perception of comfort and well-being are parallel to the pain reduction and improvement of void symptoms 1

Evolution of pain or bladder symptoms: Perception of comfort and well-being are parallel to the pain reduction and improvement of void symptoms

After therapy

  • VAS reduction > 2 in 85.4% of patients
  • VAS reduction < 2 in 6.3% of patients
  • No VAS reduction in only 8.3% of patients

Average number of instillations: 11.8 (8-25)

50 % of the patients may be regarded as cured after only a primary therapy of Cystistat®* 1



Prevention of Recurrent Bacterial Cystitis RBC

Cystistat®, a regenerative role to stop recurrences

Cystistat® is more effective than antibio-prophylasis 5,6

Cystistat® reduces significantly the number of UTIs per year 5

  • Cystistat® increased significantly the median time to recurrence (96 to 498 days, p<0.001).5
  • 70 % of the patients with Cystistat® were recurrence-free after 1 year of follow-up.5

Time to UTI recurrent (before and after treatment)

Time to UTI recurrent (before and after treatment)


Radiation-induced cystitis (RIC)

Cystistat® demonstrated an effect in the prevention and treatment of RIC

  • Cystistat® is significantly active on acute and late toxicity (5 year follow-up).7
  • Cystistat® decreases the incidence and the degree of acute and late bladder toxicity. 7